Medpage Today on MSN4d
Managing Primary Biliary Cholangitis Progression and Symptoms
Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...
Medpage Today on MSN4d
Primary Biliary Cholangitis Incidence and Prevalence Growing
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected ...
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...
PoliticsHome6d
Turning ambition into action: improving care for women with primary biliary cholangitis
Primary biliary cholangitis (PBC) may be rare, but its impact on women can be profound, leaving too many undiagnosed for ...
PharmiWeb14h
Iqirvo® (elafibranor) data show efficacy and tolerability for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen presents three late-breaking presentations and eight abstracts across rare cholestatic liver disease portfolio at AASLD 2024Elafibranor was granted marketing authorisation for the treatment of ...
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
INTEGRIS-PSC featured in an oral late breaker presentationSOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, ...
Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management
Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which ...